BioAlliance Pharma wins approval for Setofilm
Paris - AIDS and cancer specialist BioAlliance Pharma SA has won approval for Setofilm in 16 European countries. Setofilm® is an anti-emetic drug for the prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy and post operative effects in adults and children. Setofilm is the second product launched by BioAlliance in Europe after Loramyc approval. In Europe, anti-emetic drugs represent a large segment of cancer supportive care market with sales of nearly €400 million in the five largest markets (IMS Health data, 2009). Ondansetron is the leading drug of its class with a 74% market share as of end 2009. BioAlliance Pharma acquired Setofilm commercialization rights for Europe in 2008 from Swiss Applied Pharma Research SA. The product is based on a proprietary oral film strip technology platform developed by APR and Labtec GmbH.